GlaxoSmithKline announced it has begun shipping the first lots of 2012-2013 FluLaval (influenza virus vaccine) and Fluarix (influenza virus vaccine) to CDC distribution centers and U.S. healthcare providers. This follows approval of this season’s GSK seasonal influenza vaccines by the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research.
Beginning with today’s initial shipments, GSK flu vaccine will be available to most healthcare providers in time to address back-to-school immunization needs of parents and children. Subsequently, the company anticipates being able to supply its seasonal flu vaccines to the U.S. marketplace into 2013.
FluLaval is approved for use in adults (≥18 years of age) for active immunization against influenza disease caused by the virus subtypes A and B contained in the vaccine. Fluarix is approved for use in adults and children ≥3 years of age for active immunization for the prevention of influenza disease caused by the virus subtypes A and B contained in the vaccine.
For more information call (888) 825-5249 or visit www.gsk.com.